We will continue taking on challenges to build a more sustainable society.
Since its founding in 1934, the Fujifilm Group has continued to be a leading company in the field of photography, and at the same time, we have adapted our business portfolio to meet the changing needs of the world and have continued to provide new value to society. In January 2024, we will celebrate the 90th anniversary of our founding.
Looking ahead to the future, the Fujifilm Group is promoting various initiatives with the aim of continuing to contribute to the resolution of social issues and the realization of a sustainable society for the 100th anniversary and beyond. To further the realization of a decarbonized society, the Group has targeted net zero CO2 emissions from our energy consumption by the Fiscal Year ending March 2041 (FY2040). We have also targeted a 50% reduction of CO2 emissions across the entire product life cycle by FY2030, as compared to FY2019 levels. Furthermore, we are promoting business activities that fulfill our mission of "contributing to solving social issues through business activities." This includes, for example, activities to end tuberculosis, which has become a social issue facing many developing countries.
Especially, our Group focuses on creating products and services that contribute to digital transformation (DX), which is revolutionizing business systems making full use of digital technologies such as artificial intelligence (AI). We are creating sustainable innovation across the group by enhancing innovative technologies while creating new business value.
In our highly focused Healthcare segment, we provide cutting-edge products and services that address unmet medical needs, improve access to medical care, and detect diseases in their early stages. In our medical diagnostic segment, we are creating new value with our extensive portfolio of CT, MRI, X-ray diagnostic equipment, ultrasound and endoscopy systems, based on highly advanced image processing, AI, and proprietary technologies. Furthermore, our Contract Development and Manufacturing Organization (CDMO) business for biologics is facilitating a stable supply of high-quality biopharmaceuticals and promoting process development and manufacture of gene and cell therapy drugs in the field of advanced medical treatment.
In FY2022, we achieved record-high revenue, operating income, and net income attributable to FUJIFILM Holdings, and achieved the targets set in our mid-term management plan “VISION2023” one year ahead of schedule. The Fujifilm Group will continue to strive for sustainable growth and increased corporate value through its business activities, while aiming to contribute to the sustainable development of society.
President, Representative Director & Chief Executive Officer
Special Contents & Movies
Introducing past movies of our president, Teiichi Goto.